Figure 4.
Influence of the 7-day intravenous administration of O-1602 (0.25 mg/kg/day) on the levels of (A) interleukin 1-β (IL-1β) (B) tumor necrosis factor alpha (TNF-α), (C) corticotropin-releasing factor (CRF), (D) brain-derived neurotrophic factor (BDNF), and (E) nerve growth factor (NGF) in the hippocampus of rats subjected to the 14-day corticosterone treatment (20 mg/kg/day, subcutaneously). The values represent the mean + SEM (n = 14-15 animals per group). ***p < 0.001 versus vehicle-treated group, ^^^p < 0.001 versus corticosterone-treated group (Bonferroni’s post hoc test).